William Bond, MD
Ophthalmology · Pekin, ILNPI 1184653644
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,326 of the $5,068 with a category attached, or 65.6%. 20 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 43.0% of the total. Reporting peaked in 2019 at $2,721 and has fallen 92.4% since, to $206 in 2024.
Across 96 payments — averaging $52.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$2K
- Alcon$645
- AbbVie$457
- Bausch & Lomb, A Division Of Bausch Health US, LLC$417
- Kala Pharmaceuticals, Inc.$319
- Bausch & Lomb Americas Inc.$182
- plus $868 from 14 others
Across 2 payments — averaging $29,031 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$58K
What the payments were for
- Travel & lodging$1,69733%
- Food & beverage$3,32666%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 9 | $2,181 |
| Alcon | 16 | $645 |
| AbbVie(2 entities) | 26 | $457 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $417 |
| Kala Pharmaceuticals, Inc. | 5 | $319 |
| Bausch & Lomb Americas Inc. | 8 | $182 |
| Carl Zeiss Meditec, Inc. | 3 | $163 |
| Regeneron Healthcare Solutions, Inc. | 2 | $162 |
| Bausch Health US, LLC | 1 | $102 |
| Amgen | 2 | $95 |
| Novartis | 4 | $74 |
| Iridex Corporation | 1 | $66 |
| Aerie Pharmaceuticals, Inc. | 3 | $51 |
| Merz Pharmaceuticals, LLC | 1 | $35 |
| Ivantis, Inc | 1 | $26 |
| Oyster Point Pharma, Inc. | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Thea Pharma Inc. | 1 | $20 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Biotissue Holdings Inc. | 2 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis 1-piece IOL$1,812
- Tecnis Multifocal Family of 1-piece IOLS$1,812
- Tecnis Symfony IOL$1,812
- INVELTYS$267
- EYSUVIS$267
- AcrySof IQ VIVITY IOL$139
- Tecnis IOL$129
- Rocklatan$120
- Rhopressa$120
- AcrySof IQ PanOptix$101
How this compares
$5,068 in reported general payments places this provider in the 80th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 50 | $20,689 |
| RestasisCyclosporine | 25 | $12,117 |
| XiidraLifitegrast | 11 | $11,580 |
| Latanoprost | 1,326 | $11,540 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 47 | $8,952 |
| Brimonidine Tartrate | 134 | $8,228 |
| Alphagan PBrimonidine Tartrate | 37 | $7,947 |
| Timolol Maleate | 903 | $5,973 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $5,655 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $3,384 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $3,153 |
| Prednisolone Acetate | 81 | $3,098 |
| Travoprost | 17 | $2,089 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 157 | $1,740 |
| Dorzolamide Hcl | 97 | $1,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $457 | $44,137129 claims |
| Bausch & Lomb Americas Inc.Xiidra | $182 | $11,58011 claims |
| AlconSimbrinza | $645 | $8,95247 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $51 | $5,65514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Pekin
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.